Sumitomo Mitsui Trust Group Inc. Has $1.86 Million Stock Holdings in Medpace Holdings, Inc. $MEDP

Sumitomo Mitsui Trust Group Inc. decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 21.4% during the 1st quarter, Holdings Channel reports. The fund owned 3,872 shares of the company’s stock after selling 1,055 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Medpace were worth $1,859,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. NewEdge Advisors LLC boosted its position in shares of Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock worth $319,000 after purchasing an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after buying an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in Medpace during the 2nd quarter worth $296,000. Finally, M&T Bank Corp raised its stake in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock worth $295,000 after buying an additional 31 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Down 1.3%

Shares of NASDAQ MEDP opened at $529.23 on Thursday. The firm has a market cap of $15.11 billion, a PE ratio of 33.26, a PEG ratio of 2.72 and a beta of 1.15. Medpace Holdings, Inc. has a 1-year low of $306.70 and a 1-year high of $628.92. The company has a fifty day moving average price of $473.64 and a 200 day moving average price of $494.66.

Medpace (NASDAQ:MEDP) last released its earnings results on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the prior year, the company earned $3.67 EPS. The company’s revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Wall Street Analyst Weigh In

MEDP has been the topic of several recent analyst reports. Royal Bank Of Canada reduced their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Medpace in a research report on Thursday, July 2nd. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Robert W. Baird reiterated a “neutral” rating and issued a $547.00 price objective (up from $477.00) on shares of Medpace in a research report on Wednesday, July 8th. Finally, Barclays lowered their target price on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Two investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $469.50.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.